These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35378710)

  • 1. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
    Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
    FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
    Liu H; Qian F
    Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake.
    Nikolaou S; Juin A; Whitelaw JA; Paul NR; Fort L; Nixon C; Spence HJ; Bryson S; Machesky LM
    Elife; 2024 May; 13():. PubMed ID: 38712822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
    Seguin L
    Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
    Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
    ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
    Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
    Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
    Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
    Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.
    Brambillasca S; Cera MR; Andronache A; Dey SK; Fagá G; Fancelli D; Frittoli E; Pasi M; Robusto M; Varasi M; Scita G; Mercurio C
    Biomed Pharmacother; 2024 Aug; 177():116991. PubMed ID: 38906021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
    Hou P; Ma X; Yang Z; Zhang Q; Wu CJ; Li J; Tan L; Yao W; Yan L; Zhou X; Kimmelman AC; Lorenzi PL; Zhang J; Jiang S; Spring D; Wang YA; DePinho RA
    Genes Dev; 2021 Oct; 35(19-20):1327-1332. PubMed ID: 34531315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
    Liu X; Ghosh D
    Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
    Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
    J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.
    Sung S; Choi J; Cheong H
    Oncotarget; 2015 Dec; 6(38):40405-17. PubMed ID: 26575954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
    Moss DY; McCann C; Kerr EM
    Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
    Crawford HC
    Genes Dev; 2021 Oct; 35(19-20):1325-1326. PubMed ID: 34599002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.